Comparative Analysis of the Sexually Transmitted Pathogens Spectrum in Patients with Benign Hyperplasia and Prostate Cancer
##plugins.themes.bootstrap3.article.sidebar##
##plugins.themes.bootstrap3.article.main##
Abstract
The objective: comparison of infection with sexually transmitted pathogens (STDs), according to the study of genital excrement and intraoperatively removed prostate gland (PZ) in patients with benign prostatic hyperplasia (BPH) and prostate cancer.
Materials and methods. 317 patients aged 42 to 83 years (mean age 62 years) were examined. The first group included 122 patients with RP who underwent radical prostatectomy. The second group included 195 patients with BPH, who underwent a planned intermittent prostatectomy in the urological departments of theAlexanderClinicalHospital in Kyiv.
Results. The obtained results indicates that STDs DNA in genital excreta and in the removed prostatic tissue in patients with BPH 1.8 times more likely than in patients with the PC. The most common STDs pathogen, detected in the genital excreta and intraoperatively removed prostatic tissue in patients with BPH and PC is Trichomonas vaginalis, which is identified in 26.2% and 14.8% of patients, respectively. In all patients with prostate tumours mollicutes are found more often in the genital excreta than in the intraoperatively removed tissue of the prostate gland (2.4 times more often in patients with BPH and 2 times more often in patients with PC). Trichomonas vaginalis vice versa is found less frequently in genital excreta than in the intraoperatively removed prostate tissue: at BPH 1.1 times rare and at PC 2 times rare. The overall incidence of STD pathogens in removed prostate hyperplasia tissue in patients with BPH is 3.3 times higher than that in prostate cancer patients (p<0.001).
Conclusion. The established facts require further study of this problem in order to improve the understanding of the potential role of STD pathogens in the etiopathogenesis of prostate tumors and its impact on the treatment of these tumors.##plugins.themes.bootstrap3.article.details##
This work is licensed under a Creative Commons Attribution 4.0 International License.
Authors retain the copyright and grant the journal the first publication of original scientific articles under the Creative Commons Attribution 4.0 International License, which allows others to distribute work with acknowledgment of authorship and first publication in this journal.
References
Возіанов СО, Сайдакова НО, Григоренко ВМ, Онищук АП, Щниськів ОО. Причина, загальна захворюваність, смертність від основних хвороб органів сечостатнвої системи в аспекті діяльності ДУ «Інститут урології НАМН України». Урологія. 2015;19(3):15-28.
Лесовой ВН, Хареба ГГ, Гарагатый ИА, Щукин ДВ, Демченко ВН. Результаты хирургического лечения рака простаты в Харьковском регионе. Урологія. 2015;19(3):61-63.
Головачев СВ, Нургалиев НС, Камарли ЗП, Макимбетов ЭК. Состояние онкологической помощи и эпидемиология рака предстательной железы в центроазиатских республиках. Онкоурология. 2016;3(том12):82-6.
Akaza H. Epidemiology and prevention. Nihon Rinsho. 2016;74(1):13-9.
Brawley OW. Prostate cancer epidemiology in the United States. World J Urol. 2012;30(2):195-200.
MacLennan G. The influence of chronic inflammation in prostatic carcinogenesis: a 5-year followup study / G. MacLennan, R. Eisenberg, R. Fleshman. – J Urol, 2006. – 176(3):1012-6.
Maitland N. Inflammation as the primary aetiological agent of human prostate cancer: a stem cell connection? / N. Maitland, A. Collins. – J. Cell. Biochem, 2008. – 105(4):931-9.
Klein E. Inflammation, infection, and prostate cancer / E. Klein, R. Silverman. – Curr Opin Urol, 2008. – 18(3):315-9.
Hsing AW, Chokkalingam AP. Prostate cancer epidemiology. Front Biosci. 2006;11:1388–1413.
Ries LG, Melbert D, Krapcho M, Mariotto A, Miller BA, Feuer EJ, Clegg L, Horner MJ, Howlader N, Eisner MP, Reichman M, Edwards BK, Eds. Cancer Statistics Review, 1975-2004. National Cancer Institute, Bethesda, MD, 2007.
Platz EA, De Marzo AM. Epidemiology of inflammation and prostate cancer. J. Urol. 2004;171:36–40.
Huang WY, Hayes R, Pfeiffer R, Viscidi RP, Lee FK, Wang YF, Reding D, Whitby D, Papp JR, Rabkin CS: Sexually Transmissible Infections and Prostate Cancer Risk. Cancer Epidemiol Biomarkers Prev. 2008, 17 (9): 2374-2381.
Dennis KL, Coughlin JA, McKinnon BC, Wells TS, Gaydos CA, Hamsikova E, Gray GC: Sexually transmitted infections and prostate cancer among men in the U.S. Military. Cancer Epidemio Biomarkers Prev. 2009, 18 (10): 2665-2671.
Lian W.Q., et al. Gonorrhea and Prostate Cancer Incidence: An Updated Meta-Analysis of 21 Epidemiologic Studies. Med Sci Monit, 2015. 21: 1902.
Россихин В.В. Егоров И.А., Базаринский О.Г., Реуцкий Н.И. Аденома предстательной железы и простатиты (диагностика, комплексное лечение и профилактика) с использованием фитотерапии. Х.:[б. и.]. 2004;118.
Гориловский Л.М. Эпидемиология и факторы риска доброкачественной гиперплазии предстательной железы / Л.М. Гориловский. – М.: Пьер Фабр., 1997. – С. 10–18.
Wang W. Chronic inflammation in benign prostate hyperplasia is associated with focal upregulation of cyclooxygenase-2, Bcl-2, and cell proliferation in the glandular epithelium / W. Wang, A. Bergh, J. E. Damber // Prostate. – 2004. – Vol. 61, № 1. – P. 60–72.
Bedalov G. Prostatis in bening prostatic hyperplasia: a histological, bacteriological and clinical study / G. Bedalov, I. Vuckovic, S. Fridrih [et al.] // Acta. Med. Croat. – 1994. – Vol. 48. – P. 105–109.
Nickel J.C. Asymptomatic inflammation and/or infection in benign prostatic hyperplasia. / J.C. Nickel, J. Downey, I. Young [ et al.] // B.J.U. International. – 1999. – Vol. 84. – P. 976–981.
Taoka R. Association of prostatic inflammation with downregulation of macrophage inhibitory cytocine–1 gene in symptomatic begin prostatic hyperplasia / R. Taoka, F. Tsukuda, M. Ishikawa [et al.] // Am. J. Physiol. – 2004. – Vol. 171 (Part 1). – P. 2330–2335.
Cerutti P. Inflamation and oxidative stress in cancerogenesis / P. Cerutti, B. Trump. – Cancer Cells, 1997. – 3:1-7.
Переверзев АС. Воспаление и рак простаты. Урология. 2011;4 (59): 59-69.
Miersch W.D. BPH from molecular biology to patient relief / W.D. Miersch, C.A. Bierhoff Dimopoulosr, F.Di Silverio // Monduzzi Editore. – 1996. – Vol. 4. – P. 35–40.
Yamanishi T. Correlation between lower urinary tract symptoms and urethral function in benign prostatic hyperplasia / T. Yamanishi, K. Yasuda, S. Kitahara, T. Suzuki // Neurourol. Urodyn. – 2004. – Vol. 23, № 7. – P. 618-622.
Датуашвили Т.Д. Низкоэнергетическое лазерное излучение (НЭЛИ) в терапии больных аденомой предстательной железы и сопутствующим хроническим простатитом / Т.Д. Датуашвили, В.П. Дьяконов, Г.Б. Яцевич, А.А. Лахмотко // Тез. докладов Пленума Всерос. общ-ва урологов, 27–29 октября, 1994 г., г. Саратов – Саратов : [б.и.], 1994. – С. 40–41.
Пивоваров П.И. Современные подходы к диагностике и лечению заболеваний простаты / П.И. Пивоваров, Х. Кубильос, А.М. Пушкарь. – Винница: [б. и.], 1999. – 186 с.
Bastian P, Nuhn P, Stadler T, et al. Prostatitis und Prostatakarzinom. Urologe. 2010;49:636-638.
Roberts R, Bergstralh E, Bass S, et al. Prostatitis as a risk factor for prostate cancer. Epidemiology. 2004;15:93-99.
Wagenlehner F, Elkahwaji J, Algaba F, et al. The role of inflammation and infection in the pathogenesis of prostate carcinoma. BJU Int. 2007;100(4):733-7.
Мягкий В.М Оперативные вмешательства при ДГПЖ / В.М. Мягкий, В.М. Вовк, Ю.А. Червоный [и др.] // Здоровье мужчины: мат-лы XII науч.-практ. конф. урологов и сексопатологов, 20–21 мая, 2004 г., г. Харьков. – 2004. – Х.: [б. и.], 2004. – С. 125–127.
Горпинченко І.І. Порівняльна характеристика медикаментозних методів лікування аденоми передміхурової залози / І.І. Горпинченко, М.І. Бойко, В.В. Страшний // Урологія. – 1998. – № 2. – С. 53–56.
Daniels N. Correlates and prevalence of prostatitis in a large community-based cohort of older men / N. Daniels, S. Ewing, J. Zmuda. – Urology, 2005. – 66(5):964-70.
Lee K.L., Peehl D.M. Molecular and cellular pathogenesis of benign prostatic hyperplasia. // J. Urol. – 2004. – Vol. 172, № 5. – P. 1784–1791.
Лоран О.Б., Пушкарь Д.Ю., Раснер П.И. Сравнительная оценка эффективности и безопасности комбинированной медикаментозной терапии больных с доброкачественной гиперплазией простаты препаратами финастеридом и альфузозином.Урология. 2002;1:19-22.
